Segall Bryant & Hamill LLC Purchases New Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Segall Bryant & Hamill LLC bought a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 289,075 shares of the company's stock, valued at approximately $5,891,000. Segall Bryant & Hamill LLC owned about 0.20% of Denali Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Victory Capital Management Inc. raised its holdings in Denali Therapeutics by 163.7% in the 3rd quarter. Victory Capital Management Inc. now owns 39,900 shares of the company's stock valued at $1,162,000 after acquiring an additional 24,767 shares during the last quarter. Quest Partners LLC purchased a new stake in shares of Denali Therapeutics in the third quarter valued at approximately $73,000. Intech Investment Management LLC acquired a new stake in shares of Denali Therapeutics in the third quarter valued at approximately $861,000. Algert Global LLC increased its holdings in shares of Denali Therapeutics by 82.4% in the third quarter. Algert Global LLC now owns 48,630 shares of the company's stock valued at $1,417,000 after purchasing an additional 21,975 shares during the last quarter. Finally, Pitcairn Co. purchased a new position in Denali Therapeutics during the third quarter worth approximately $328,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Trading Down 8.0 %

DNLI traded down $1.18 during mid-day trading on Monday, hitting $13.60. 3,555,583 shares of the stock were exchanged, compared to its average volume of 1,034,838. The company has a market cap of $1.97 billion, a PE ratio of -4.93 and a beta of 1.46. The firm's fifty day moving average is $18.88 and its two-hundred day moving average is $23.11. Denali Therapeutics Inc. has a 1-year low of $13.30 and a 1-year high of $33.33.

Remove Ads

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.08. As a group, research analysts anticipate that Denali Therapeutics Inc. will post -2.71 earnings per share for the current year.

Insider Buying and Selling

In other Denali Therapeutics news, Director Vicki L. Sato sold 3,080 shares of Denali Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total transaction of $64,402.80. Following the completion of the sale, the director now directly owns 107,976 shares of the company's stock, valued at $2,257,778.16. The trade was a 2.77 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Steve E. Krognes sold 3,339 shares of the stock in a transaction dated Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total value of $69,484.59. Following the completion of the transaction, the director now owns 25,757 shares in the company, valued at approximately $536,003.17. The trade was a 11.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 47,940 shares of company stock worth $973,442 over the last 90 days. 7.90% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DNLI. Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a research note on Tuesday, February 11th. They issued a "buy" rating and a $31.00 target price for the company. Baird R W upgraded shares of Denali Therapeutics to a "strong-buy" rating in a research report on Tuesday, January 7th. Robert W. Baird began coverage on shares of Denali Therapeutics in a research note on Tuesday, January 7th. They set an "outperform" rating and a $31.00 target price on the stock. Bank of America dropped their price target on shares of Denali Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a research note on Monday, March 10th. Finally, The Goldman Sachs Group reduced their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a "buy" rating on the stock in a research report on Tuesday, January 28th. Two investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Denali Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $37.20.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.